摘要
目的:观察丁苯酞联合阿替普酶静脉溶栓治疗急性脑梗死患者的效果。方法:选取2018年10月至2022年10月该院收治的120例急性脑梗死患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各60例。对照组采用阿替普酶静脉溶栓治疗,观察组在对照组基础上联合丁苯酞软胶囊口服治疗,比较两组美国国立卫生研究院卒中量表(NIHSS)评分、血清炎性因子[白细胞介素(IL)-2、IL-6、CXC趋化因子配体12(CXCL12)、重组人可溶性CD40配体(sCD40L)]水平、血清神经元特异性烯醇化酶(NSE)水平、血清同型半胱氨酸(Hcy)水平、简易精神状态检查量表(MMSE)评分和不良反应发生率。结果:治疗后,两组MMSE评分高于治疗前,且观察组高于对照组,两组NIHSS评分和血清CXCL12、sCD40L、IL-6、IL-2、NSE、Hcy水平低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:丁苯酞联合阿替普酶静脉溶栓治疗急性脑梗死患者可提高MMSE评分,降低血清NSE、Hcy、炎性因子水平和NIHSS评分,效果优于单纯阿替普酶静脉溶栓治疗。
Objective:To observe effects of Butylphthalide combined with Alteplase intravenous thrombolysis in treatment of patients with acute cerebral infarction.Methods:A prospective study was conducted on 120 patients with acute cerebral infarction admitted to the hospital from October 2018 to October 2022.According to the random number table method,they were divided into observation group and control group,60 cases in each group.The control group was treated with intravenous thrombolysis with Alteplase,while the observation group was treated with oral Butylphthalide soft capsules on the basis of that of the control group.The National Institutes of Health stroke scale(NIHSS)score,the serum inflammatory factors[interleukin(IL)-2,IL-6,C-X-C chemokine ligand 12(CXCL12),recombinant human soluble CD40 ligand(sCD40L)]levels,the serum neuron specific enolase(NSE)level,the serum homocysteine(Hcy)level,the mini-mental state examination(MMSE)score,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the MMSE scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the NIHSS score and the serum levels of CXCL12,sCD40 L,IL-6,IL-2,NSE and Hcy in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Butylphthalide combined with Alteplase intravenous thrombolysis in the patients with acute cerebral infarction can improve the MMSE scores,and reduce the serum NSE,Hcy,inflammatory factor levels and the NIHSS scores.Moreover,it is superior to single Alteplase intravenous thrombolysis treatment.
作者
李述震
LI Shuzhen(Department of Neurology of Xinxiang Union Hospital,Xinxiang 453000 Henan,China)
出处
《中国民康医学》
2024年第8期8-10,共3页
Medical Journal of Chinese People’s Health
作者简介
李述震(1984.01-),男,汉族,河南新乡人,本科,主治医师,研究方向为神经内科。
